LA JOLLA, Calif.–(BUSINESS WIRE)–$LBPH #Epilepsy—Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present new and encore data at the 35th International Epilepsy Congress (IEC) and the American College of Clinical Pharmacology (ACCP) Annual Meeting.
Presentation Details:
IEC September 2-6, 2023 – Dublin, Ireland
-
Title: A Phase 1 Clinical Study Shows Robust LP352 CSF Exposures Supporting Dose Optimization for 5-HT2C Receptor Engagement (#746)
Details: Digital poster
-
Title: The PACIFIC Study: A Phase 1b/2a Study to Investigate the Safety, Tolerability, Pharmacology, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies (#758)
Oral Presentation Date/Time: September 5, 2:00 PM-2:30 PM GMT
-
Title: Searching for Safer and More Effective Medications in the Management of Seizure Disorders: A 5-HT2C Superagonist (#754)
Oral Presentation Date/Time: September 5, 2:00 PM-2:30 PM GMT
-
Title: Evaluation of Prolactin as a Useful Pharmacodynamic Tool to Assess Engagement of Central 5-HT2C Receptors by LP352, a Potent and Selective 5-HT2C Agonist (#749)
Oral Presentation Date/Time: September 5, 2:00 PM-2:30 PM GMTAll posters will be available digitally throughout the duration of the conference
ACCP September 10-12, 2023 – Bellevue, WA
-
Title: A Phase 1 Study of 5-HT2C Superagonist LP352 Shows Robust Brain Penetration, a Strong Correlation Between Plasma and CSF Pharmacokinetics, and QEEG Changes Reflecting Receptor Engagement (#060)
Oral Presentation Date/Time: September 10, 5:00 PM-7:00 PM PT
ABOUT LP352
LP352 is an oral, centrally acting, 5-HT2C superagonist in development for the potential treatment of seizures associated with DEEs such as Lennox-Gastaut syndrome, Dravet syndrome, SCN2A-related epilepsies, CDKL5 deficiency disorder, and other epileptic disorders. LP352 is designed to modulate GABA and, as a result, suppress the central hyperexcitability that is characteristic of seizures. LP352 has no detected activity at the 5-HT2B and 5-HT2A receptor subtypes. 5-HT2B and 5-HT2A receptor agonism have been associated with significant adverse side effects. LP352 has novel chemistry and attributes. It was designed to be more specific and selective for the 5-HT2C receptor subtype, giving it the potential to reduce seizures in patients with DEEs while overcoming the known or perceived safety limitations of available drugs in the 5-HT2 class. LP352 is currently being evaluated in a Ph 1b/2a clinical trial (the PACIFIC Study) in participants with DEEs, with data expected around year-end 2023, as well as in additional supportive studies.
ABOUT LONGBOARD PHARMACEUTICALS
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no detectable activity on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of Developmental and Epileptic Encephalopathies. Longboard is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of multiple neurological diseases.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Longboard’s participation in the upcoming meetings and Longboard’s clinical and preclinical programs and product candidates, ability to develop product candidates and deliver medicines, and focus. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard’s expectations. Factors that could cause actual results to differ materially from those stated or implied by Longboard’s forward-looking statements are disclosed in Longboard’s filings with the Securities and Exchange Commission (SEC). These forward-looking statements represent Longboard’s judgment as of the time of this release. Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Contacts
CORPORATE CONTACT:
Megan E. Knight
Head of Investor Relations
IR@longboardpharma.com
858.789.9283